Abionyx Pharma (FRA:609) Net Margin %: -166.87% (As of Dec. 2025)

What is Abionyx Pharma Net Margin %?

Abionyx Pharma FRA:609 +1.17% 15 Net Margin % is -166.87% as of Dec. 2025. GuruFocus rates FRA:609 with a GF Score™ of 15/100 and a GF Value™ of €0.80 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 947 Biotechnology companies, Abionyx Pharma ranks worse than 54.49% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Abionyx Pharma's Net Income for the six months ended in Dec. 2025 was €-3.24 Mil. Abionyx Pharma's Revenue for the six months ended in Dec. 2025 was €1.94 Mil. Therefore, Abionyx Pharma's net margin for the quarter that ended in Dec. 2025 was -166.87%.

The historical rank and industry rank for Abionyx Pharma's Net Margin % or its related term are showing as below:

FRA:609' s Net Margin % Range Over the Past 10 Years
Min: -3623.56 Med: -116.43 Max: -75.82
Current: -136.6

FRA:609's Net Margin % is ranked worse than
54.49% of 947 companies
in the Biotechnology industry
Industry Median: -89.56 vs FRA:609: -136.60

Abionyx Pharma (FRA:609) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Abionyx Pharma Net Margin % Related Terms

Abionyx Pharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Abionyx Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abionyx Pharma Net Margin % Chart

Abionyx Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Net Margin %

Get a 7-Day Free Trial

-862.52

-80.08

-75.82

-96.26

-136.60

Abionyx Pharma Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Net Margin %	Get a 7-Day Free Trial															-50.56	-89.08	-103.90	-108.82	-166.87

FRA:609 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Abionyx Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abionyx Pharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's Net Margin % falls into.

Save Embed

15GF Score

Abionyx Pharma FRA:609

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Abionyx Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Abionyx Pharma's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-5.55	/	4.063
	=	-136.60 %

Abionyx Pharma's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	-3.244	/	1.944
	=	-166.87 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of -166.87% mean?

Abionyx Pharma (FRA:609) has a Net Margin % of -166.87% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Abionyx Pharma and its competitors. According to the industry distribution chart, Abionyx Pharma ranks #516 out of 947 companies in the Biotechnology industry, placing it in the top 54.5%.

Is Abionyx Pharma's Net Margin % too high?

Abionyx Pharma's current Net Margin % is -166.87%. Based on the distribution chart, Abionyx Pharma ranks #516 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Abionyx Pharma has a GF Score™ of 15/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Abionyx Pharma's Net Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Abionyx Pharma ranks #516 out of 947 companies for Net Margin %. This places Abionyx Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Abionyx Pharma and its competitors. Abionyx Pharma's current Net Margin % is -166.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Abionyx Pharma stock overvalued right now?

Based on GuruFocus' analysis, Abionyx Pharma (FRA:609) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.80, compared to a current price of €2.17 — trading 171.3% above its estimated fair value. The current Net Margin % is -166.87%. Abionyx Pharma's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Abionyx Pharma (FRA:609), the current Net Margin % is -166.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abionyx Pharma (FRA:609) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €2.17 is trading 171.3% above its estimated GF Value™ of €0.80. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for FRA:609:

Net Margin %: -166.87%
GF Value™: €0.80 vs. price of €2.17 (171.3% above fair value)
GF Score™: 15/100 with 4 warning signs

No single metric tells the full story. See the FRA:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies XPAR:OSE XPAR:ALVIO XPAR:ADOC XPAR:ALGAE XPAR:ALTHX XPAR:MAAT XPAR:IPH XPAR:ALCOX XPAR:MLINA XPAR:ALGEN VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 0RAG:UK ABNX:France 609:Germany

Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130

Website https://www.abionyx.com

Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

15GF Score

Get the complete analysis for FRA:609

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.17

Price

€0.80

GF Value

View FRA:609 Analysis

See Net Margin % data for all stocks →